Summary of BIO-key International's Q4 2025 Earnings Call

1Key Financial Results and Metrics

2025 Revenue: Decreased by 12% to $6.1 million from $6.9 million in 2024.

Q4 2025 Revenue: License Fee revenue fell by 26%, while Hardware revenue surged by 85% and Service revenue decreased by 10%.

Gross Margin: 77.5% for 2025, down from 81.4% in 2024, but improved to 91% for License Fee revenue.

Net Loss: Increased to $4.6 million ($0.69 per share) for 2025, compared to $4.3 million ($2.09 per share) in 2024. Q4 net loss was $1.7 million ($0.19 per share), up from $1.4 million ($0.46 per share) in 2024.

Cash Position: Ended 2025 with $2.7 million in cash, up from $438,000 in 2024. Book value increased to $7.6 million from $3.8 million.

2Strategic Updates and Business Highlights

Transitioned to selling only BIO-key-branded solutions in EMEA, expected to enhance gross margins and growth prospects.

Launched the Defense & Intelligence Cybersecurity Initiative in 2025, with notable contract wins in defense and financial sectors.

Introduced the EcoID III fingerprint scanner, aimed at highly regulated industries.

Significant focus on R&D, with a major update to the PortalGuard Identity platform (Version 7.0) expected in Q2 2026.

3Forward Guidance and Outlook

Anticipates Q1 2026 revenue of approximately $2.2 million, representing a 37% increase over Q1 2025.

Expects substantial improvement in Q1 2026 bottom line performance, aiming for breakeven and profitability in 2026.

The enterprise authentication market is projected to grow significantly, with increasing demand for secure access solutions.

4Bad News, Challenges, or Points of Concern

2025 revenue performance was disappointing, primarily due to timing issues with a significant contract renewal that impacted recognized revenue.

The transition in the EMEA region took longer than expected, affecting revenue growth.

The company faces competitive pressures in the authentication market, particularly from larger competitors.

Potential risk of a reverse stock split if the share price does not exceed $1 for 10 consecutive days before early May 2026.

5Notable Q&A Insights

Clarified that the $1 million contract renewal with a foreign bank represents a 30% increase and is a continuation of a previous two-year contract.

Emphasized strong optimism for 2026, citing urgency from customers in regulated industries for enhanced security solutions.

Discussed ongoing partnerships, particularly with TD Synnex, which are expected to drive growth in the public sector.

Addressed concerns about expenses, indicating stability and a focus on cost management while investing in R&D.

Confirmed that the company is in a strong position to achieve breakeven and profitability, with a focus on subscription-based revenue and multi-year contracts. Overall, BIO-key International is navigating a challenging financial landscape but is optimistic about future growth driven by strategic initiatives and market demand for enhanced security solutions.